Roberto Testa

Roberto Testa

Auto-generated profile, based on publicly available information

Roberto Testa

Gastroenterology Unit, Department of Internal Medicine, University of Genoa, Genoa, Italy

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2003 in Gut
Verified
Journal Article
Open access
PDF file
Edoardo Giovanni GianniniEdoardo Giovanni Giannini
Edoardo Giovanni Giannini
FBF Botta
F Botta
PBP Borro
P Borro
DRD Risso
D Risso
PRP Romagnoli
P Romagnoli
RTR Testa
R Testa
Background and aims: Cirrhotic patients frequently undergo screening endoscopy for the presence of oesophageal varices (OV). In the future, this social and medical burden will increase due to the greater number of patients with chronic liver disease and their improved survival. In this study, our aims were (1) to identify clinical, biochemical, and ultrasonographic parameters which might non-invasively predict the presence of OV in patients with liver cirrhosis; (2) to evaluate the reproducibility of the obtained results in a different, although related, further group of patients; and (3) to assess the predictiveness of the identified rules in patients with compensated cirrhosis. Methods: In the first part of the study we retrospectively evaluated the presence of OV in 145 cirrhotic patients, and in the second part we evaluated the reproducibility of the study results in a subsequent group of 121 patients. Finally, we evaluated these parameters in a subgroup of 145 patients with compensated disease. All 266 patients underwent a complete biochemical workup, upper digestive endoscopy, and ultrasonographic measurement of spleen bipolar diameter. Platelet count/spleen diameter ratio was calculated for all patients. Results: The prevalence rates of OV were 61% and 58% in the first and second groups of patients, respectively. In the first part of the study, we found that platelet count, spleen diameter, platelet count/spleen diameter ratio, and Child- Pugh class were significantly different among patients with or without OV, although the platelet count/spleen diameter ratio was the only parameter which was independently associated with the presence of OV in a multivariate analysis. A platelet count/spleen diameter ratio cut off value of 909 had 100% negative predictive value for a diagnosis of OV. This result was reproduced in the second group of patients as well as in patients with compensated disease. In a cost-benefit analysis, screening cirrhotic patients according to the “platelet count/spleen diameter ratio strategy” was far more cost effective compared with the “scope all strategy”. Conclusions: The platelet count/spleen diameter ratio is the only parameter which is independently associated with the presence of OV, and its negative predictive value is reproducible. Its use is of value even in the subgroup of patients with compensated disease, and it is also cost effective.

27 January 2003 in Archives of internal medicine (1960)
Verified
Journal Article
Open access
PDF file
Edoardo Giovanni GianniniEdoardo Giovanni Giannini
Edoardo Giovanni Giannini
DRDomenico Risso
Domenico Risso
FBFederica Botta
Federica Botta
BCBruno Chiarbonello
Bruno Chiarbonello
AFAlberto Fasoli
Alberto Fasoli
RTRoberto Testa
Roberto Testa
THE RATIO of aspartate aminotransferase to alanine aminotransferase (AST/ALT ratio) has been evaluated in previous studies1-6 conducted on patients with acute and chronic liver disease (CLD) of various origins. In these patients, the AST/ALT ratio provided useful clinical information regarding both cause and severity of liver disease. Since this variable is readily available, easy to interpret, and inexpensive, it has been applied to various studies performed during the past decade.

1 January 2003 in Gut
Verified
Journal Article
Open access
PDF file
FBF Botta
F Botta
Edoardo Giovanni GianniniEdoardo Giovanni Giannini
Edoardo Giovanni Giannini
PRP Romagnoli
P Romagnoli
AFA Fasoli
A Fasoli
FMF Malfatti
F Malfatti
RTR Testa
R Testa
Background: Indices for predicting survival are essential for assessing prognosis and assigning priority for liver transplantation in patients with liver cirrhosis. The model for end stage liver disease (MELD) has been proposed as a tool to predict mortality risk in cirrhotic patients. However, this model has not been validated beyond its original setting. Aim: To evaluate the short and medium term survival prognosis of a European series of cirrhotic patients by means of MELD compared with the Child-Pugh score. We also assessed correlations between the MELD scoring system and the degree of impairment of liver function, as evaluated by the monoethylglycinexylidide (MEGX) test. Patients and methods: We retrospectively evaluated survival of a cohort of 129 cirrhotic patients with a follow up period of at least one year. The Child-Pugh score was calculated and the MELD score was computed according to the original formula for each patient. All patients had undergone a MEGX test. Multivariate analysis was performed on all variables to identify the parameters independently associated with one year and six month survival. MELD values were correlated with both Child-Pugh scores and MEGX test results. Results: Thirty one patients died within the first year of follow up. Child-Pugh and MELD scores, and MEGX serum levels were significantly different among patients who survived and those who died. Serum creatinine, international normalised ratio, and MEGX60 were independently associated with six month mortality while the same variables and the presence of ascites were associated with one year mortality. MELD scores showed significant correlations with both MEGX values and Child-Pugh scores. Conclusions: In a European series of cirrhotic patients the MELD score is an excellent predictor of both short and medium term survival, and performs at least as well as the Child-Pugh score. An increase in MELD score is associated with a decrease in residual liver function.


28 January 2003 in Liver International
Verified
Journal Article
Closed access
PDF file
Edoardo Giovanni GianniniEdoardo Giovanni Giannini
Edoardo Giovanni Giannini
PCPaola Ceppa
Paola Ceppa
FBFederica Botta
Federica Botta
AFAlberto Fasoli
Alberto Fasoli
PRPaola Romagnoli
Paola Romagnoli
RTRoberto Testa
Roberto Testa

26 June 2006 in Journal of Internal Medicine
Verified
Journal Article
Closed access
PDF file
RTR. Testa
R. Testa
ETE. Testa
E. Testa
Edoardo Giovanni GianniniEdoardo Giovanni Giannini
Edoardo Giovanni Giannini
PBP. Borro
P. Borro
SMS. Milazzo
S. Milazzo
DRD. Risso
D. Risso